[Bag plasmapheresis in patients with stage IIb peripheral arterial occlusive disease]. 1988

H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
Abteilung für Klinische Hämostaseologie und Transfusionsmedizin, Universitätskliniken des Saarlandes, Homburg.

The clinical effect of bag-plasmapheresis was investigated in 60 patients with peripheral arterial occlusive disease stage II according to Fontaine. The initial number of patients was subdivided in three groups of 20 individuals using a randomised double-blind placebo-controlled design. Each patient gave 300 ml of blood twice a week for a 6 week duration. Blood plasma was separated in two groups and replaced with Hydroxyethyl-starch (200/0.5 10%) in group 1 and with Laevulose 5% in group 2. Patients in group 3 received their whole blood without any processing. All patients had to undergo a physical training of 45 minutes three times a week. The group who received Hydroxyethylstarch presented a 20% increase in walking distance whereas the increase in the Laevulose group was 5% and approximately 1% in the group receiving whole blood. The increase in walking distance in the Hydroxyethylstarch-group was significant on the 0.1%-level and significantly better than the improvement in walking distance of the other groups. Additionally in this group plasma viscosity showed a 3% decrease, erythrocyte aggregation was reduced by 10%. Results in the Laevulose group were only half as good as in the Hydroxyethylstarch group while parameters remained unchanged in the whole-blood-group. Bag plasmapheresis with Hydroxyethylstarch as substitute leads to an improvement in the walking capacity and blood fluidity thus offering a promising therapy for peripheral vascular occlusive disease.

UI MeSH Term Description Entries
D007383 Intermittent Claudication A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE. Claudication, Intermittent
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001809 Blood Viscosity The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA. Blood Viscosities,Viscosities, Blood,Viscosity, Blood
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast

Related Publications

H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
January 1988, VASA. Supplementum,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
March 2000, International angiology : a journal of the International Union of Angiology,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
January 1987, VASA. Supplementum,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
January 1992, International angiology : a journal of the International Union of Angiology,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
August 2001, Clinical chemistry and laboratory medicine,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
April 1974, Angiology,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
January 1992, VASA. Zeitschrift fur Gefasskrankheiten,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
June 1979, Die Medizinische Welt,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
December 1998, Fortschritte der Medizin,
H Kiesewetter, and J Blume, and F Jung, and M Gerhards, and S Spitzer, and G Leipnitz, and E Wenzel
January 1991, VASA. Zeitschrift fur Gefasskrankheiten,
Copied contents to your clipboard!